2013 Q3 Form 10-Q Financial Statement

#000114420413045408 Filed on August 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $880.7K $291.5K $33.04K
YoY Change 45.49% 782.16%
Cost Of Revenue $620.6K $199.6K $10.08K
YoY Change 337.52% 1879.71%
Gross Profit $260.1K $91.93K $72.96K
YoY Change -43.89% 25.99%
Gross Profit Margin 29.53% 31.54% 220.82%
Selling, General & Admin $687.8K $600.8K $293.2K
YoY Change 91.25% 104.93% 52.86%
% of Gross Profit 264.46% 653.57% 401.83%
Research & Development $294.2K $708.2K $715.8K
YoY Change -46.92% -1.06% -16.27%
% of Gross Profit 113.12% 770.34% 980.99%
Depreciation & Amortization $20.00K $20.00K $10.00K
YoY Change 100.0% 100.0% -50.0%
% of Gross Profit 7.69% 21.76% 13.71%
Operating Expenses $1.140M $1.499M $1.082M
YoY Change 7.07% 38.46% -2.84%
Operating Profit -$879.8K -$1.407M -$1.010M
YoY Change 46.35% 39.36% -9.39%
Interest Expense -$84.95K -$8.147K -$37.81K
YoY Change 67.21% -78.45% -83.35%
% of Operating Profit
Other Income/Expense, Net -$84.95K -$8.147K -$37.81K
YoY Change 67.21% -78.45% -83.35%
Pretax Income -$964.8K -$1.415M -$1.047M
YoY Change 47.98% 35.11% -21.91%
Income Tax
% Of Pretax Income
Net Earnings -$964.8K -$1.415M -$1.047M
YoY Change 47.98% 35.11% -21.91%
Net Earnings / Revenue -109.55% -485.44% -3169.63%
Basic Earnings Per Share
Diluted Earnings Per Share -$98.97K -$152.3K -$135.0K
COMMON SHARES
Basic Shares Outstanding 245.1M shares 229.9M shares 194.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.300M $1.900M $1.700M
YoY Change 9.52% 11.76% -50.0%
Cash & Equivalents $2.350M $1.871M $1.742M
Short-Term Investments
Other Short-Term Assets $700.0K $200.0K $100.0K
YoY Change 600.0% 100.0%
Inventory $362.5K $476.6K $535.3K
Prepaid Expenses
Receivables $200.0K $100.0K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.644M $2.587M $2.467M
YoY Change 25.66% 4.88% -29.53%
LONG-TERM ASSETS
Property, Plant & Equipment $143.5K $142.7K $142.4K
YoY Change 43.53% 0.17% 42.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $251.4K $251.4K $287.2K
YoY Change -16.2% -12.46% -4.26%
Total Long-Term Assets $394.9K $394.1K $429.7K
YoY Change -1.26% -8.28% 7.42%
TOTAL ASSETS
Total Short-Term Assets $3.644M $2.587M $2.467M
Total Long-Term Assets $394.9K $394.1K $429.7K
Total Assets $4.039M $2.981M $2.896M
YoY Change 22.39% 2.93% -25.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $572.0K $720.6K $620.8K
YoY Change -18.28% 16.06% -22.39%
Accrued Expenses $500.0K $500.0K $500.0K
YoY Change 25.0% 0.0% -16.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.600M $900.0K $1.200M
YoY Change 60.0% -25.0%
Total Short-Term Liabilities $3.066M $2.104M $2.304M
YoY Change 45.99% -8.69% 64.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.066M $2.104M $2.304M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.066M $2.104M $2.304M
YoY Change 45.99% -8.69% 21.28%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $245.1K $234.4K $199.1K
YoY Change 17.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.61M -$13.19M $592.0K
YoY Change
Total Liabilities & Shareholders Equity $4.039M $2.981M $2.896M
YoY Change 22.39% 2.93% -25.74%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$964.8K -$1.415M -$1.047M
YoY Change 47.98% 35.11% -21.91%
Depreciation, Depletion And Amortization $20.00K $20.00K $10.00K
YoY Change 100.0% 100.0% -50.0%
Cash From Operating Activities -$560.0K -$1.020M -$1.150M
YoY Change -11.11% -11.3% 11.65%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$40.00K -$20.00K
YoY Change -200.0% 100.0% -33.33%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$10.00K -$40.00K -$20.00K
YoY Change -200.0% 100.0% -33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.010M 1.560M 1.100M
YoY Change 6.32% 41.82% -46.08%
NET CHANGE
Cash From Operating Activities -560.0K -1.020M -1.150M
Cash From Investing Activities -10.00K -40.00K -20.00K
Cash From Financing Activities 1.010M 1.560M 1.100M
Net Change In Cash 440.0K 500.0K -70.00K
YoY Change 33.33% -814.29% -107.14%
FREE CASH FLOW
Cash From Operating Activities -$560.0K -$1.020M -$1.150M
Capital Expenditures -$10.00K -$40.00K -$20.00K
Free Cash Flow -$550.0K -$980.0K -$1.130M
YoY Change -14.06% -13.27% 13.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
471337 USD
CY2012Q4 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
349841 USD
CY2013Q2 ctso Agreement To Purchase Shares Value
AgreementToPurchaseSharesValue
8500000 USD
ctso Agreement To Purchase Shares Value During Period
AgreementToPurchaseSharesValueDuringPeriod
50000 USD
ctso Change In Fair Value Of Management Units
ChangeInFairValueOfManagementUnits
USD
ctso Change In Fair Value Of Management Units
ChangeInFairValueOfManagementUnits
USD
ctso Change In Fair Value Of Management Units
ChangeInFairValueOfManagementUnits
278087 USD
ctso Common Stock Issued As Inducement To Convert Convertible Notes Payable And Accrued Interest
CommonStockIssuedAsInducementToConvertConvertibleNotesPayableAndAccruedInterest
USD
ctso Common Stock Issued As Inducement To Convert Convertible Notes Payable And Accrued Interest
CommonStockIssuedAsInducementToConvertConvertibleNotesPayableAndAccruedInterest
USD
ctso Common Stock Issued As Inducement To Convert Convertible Notes Payable And Accrued Interest
CommonStockIssuedAsInducementToConvertConvertibleNotesPayableAndAccruedInterest
3351961 USD
ctso Consulting Fees
ConsultingFees
USD
ctso Consulting Fees
ConsultingFees
USD
ctso Consulting Fees
ConsultingFees
237836 USD
CY2013Q2 ctso Convertible Notes Current Unamortized Discount
ConvertibleNotesCurrentUnamortizedDiscount
185893 USD
CY2012Q4 ctso Convertible Notes Current Unamortized Discount
ConvertibleNotesCurrentUnamortizedDiscount
178775 USD
ctso Debt Discount
DebtDiscount
188468 USD
ctso Debt Discount
DebtDiscount
87700 USD
ctso Debt Discount
DebtDiscount
1832973 USD
CY2013Q2 ctso Debt Instrument Maturity Period
DebtInstrumentMaturityPeriod
P1Y
CY2013Q2 ctso Debt Instrument Percent Of Principal Amount
DebtInstrumentPercentOfPrincipalAmount
0.5 pure
ctso Dividends Preferred Stock Seriesa Shares
DividendsPreferredStockSeriesaShares
80702 shares
ctso Dividends Preferred Stock Series B
DividendsPreferredStockSeriesB
-1194581 USD
ctso Dividends Preferred Stock Series B Shares
DividendsPreferredStockSeriesBShares
3648.70 shares
ctso Issuance Of Common Stock In Exchange For Convertible Notes Shares
IssuanceOfCommonStockInExchangeForConvertibleNotesShares
9739912 shares
ctso Issuance Of Common Stock In Exchange For Convertible Notes Value
IssuanceOfCommonStockInExchangeForConvertibleNotesValue
1226042 USD
ctso Management Units Issued
ManagementUnitsIssued
USD
ctso Management Units Issued
ManagementUnitsIssued
USD
ctso Management Units Issued
ManagementUnitsIssued
437206 USD
CY2013Q2 ctso Number Of Patents Issued
NumberOfPatentsIssued
32 pure
ctso Period In Which Certain Amount Of Stock Can Be Sold
PeriodInWhichCertainAmountOfStockCanBeSold
P2D
ctso Period In Which Common Stock Can Be Sold
PeriodInWhichCommonStockCanBeSold
P32M
ctso Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
1202905 USD
ctso Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
1241121 USD
ctso Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
12124940 USD
CY2013Q2 ctso Preferred Stock Value Not Included In Stockholders Equity
PreferredStockValueNotIncludedInStockholdersEquity
14062012 USD
CY2012Q4 ctso Preferred Stock Value Not Included In Stockholders Equity
PreferredStockValueNotIncludedInStockholdersEquity
12887817 USD
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeited In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
0.06
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeituresInPeriod
2035000 shares
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Granted In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantedInPeriodWeightedAverageGrantDateFairValue
0.03
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantsInPeriod
13985000 shares
CY2013Q2 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber
13568000 shares
CY2012Q4 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber
7394000 shares
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriod
5776000 shares
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.05
CY2013Q2 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue
0.03
CY2012Q4 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue
0.05
ctso Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
2235000 shares
CY2013Q2 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableAggregateIntrinsicValue
1169000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2013Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
84065 USD
CY2012Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
51779 USD
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15931 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12662 USD
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89574145 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
86903415 USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
USD
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001175151
ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P6Y
CY2013Q2 ctso Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M6D
CY2012Q4 ctso Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
ctso Supplemental Noncash Transactions
SupplementalNoncashTransactions
USD
ctso Supplemental Noncash Transactions
SupplementalNoncashTransactions
USD
ctso Supplemental Noncash Transactions
SupplementalNoncashTransactions
768063 USD
ctso Technology And Content Expense
TechnologyAndContentExpense
USD
ctso Technology And Content Expense
TechnologyAndContentExpense
USD
ctso Technology And Content Expense
TechnologyAndContentExpense
4550000 USD
CY2013Q2 ctso Warrant Exercise Price
WarrantExercisePrice
0.15
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
245140616 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
Cytosorbents Corp
dei Trading Symbol
TradingSymbol
ctso
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
720560 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
800670 USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
533648 USD
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
188468 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
266490 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
266490 USD
CY2013Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
181350 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
382478 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2647079 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
183556 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1186653 USD
CY2013Q2 us-gaap Assets
Assets
2981011 USD
CY2012Q4 us-gaap Assets
Assets
3339408 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
2586900 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
2939588 USD
CY2013Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
394111 USD
CY2012Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
399820 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>1. BASIS OF PRESENTATION</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q of the Securities and Exchange Commission (the "Commission") and include the results of CytoSorbents Corporation (the "Parent"), CytoSorbents, Inc., its wholly-owned operating subsidiary (the "Subsidiary"), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the "European Subsidiary"), collectively referred to as "the Company." Accordingly, certain information and footnote disclosures required in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. Interim statements are subject to possible adjustments in connection with the annual audit of the Company&#39;s accounts for the year ended December 31, 2013. In the opinion of the Company&#39;s management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) which the Company considers necessary for the fair presentation of the Company&#39;s consolidated financial position as of June 30, 2013 and the results of its operations and cash flows for the six and three month periods ended June 30, 2013 and 2012, and for the period January 22, 1997 (date of inception) to June 30, 2013. Results for the six and three months ended are not necessarily indicative of results that may be expected for the entire year. The unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company and the notes thereto as of and for the year ended December 31, 2012 as included in the Company&#39;s Form 10-K filed with the Commission on April 03, 2013.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has experienced negative cash flows from operations since inception and has a deficit accumulated during the development stage at June 30, 2013 of $102,979,296. The Company is not currently generating significant revenue and is dependent on the proceeds of present and future financings to fund its research, development and commercialization program. These matters raise substantial doubt about the Company&#39;s ability to continue as a going concern. The Company is continuing its fund-raising efforts. Although the Company has historically been successful in raising additional capital through equity and debt financings, there can be no assurance that the Company will be successful in raising additional capital in the future or that it will be on favorable terms. We believe that we have sufficient cash to fund our operations into the fourth quarter of 2013, following which we will need additional funding before we can complete additional clinical studies and continue to commercialize our products. Furthermore, if the Company is successful in raising the additional financing, there can be no assurance that the amount will be sufficient to complete the Company&#39;s plans. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The Company is a development stage company and has not yet generated significant revenues from inception to June 30, 2013. Since inception, the Company&#39;s expenses relate primarily to research and development, organizational activities, clinical manufacturing, regulatory compliance, sales and operational strategic planning. Although the Company has made advances on these matters, there can be no assurance that the Company will continue to be successful regarding these issues, nor can there be any assurance that the Company will successfully implement its long-term strategic plans.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The Company has developed an intellectual property portfolio, including 32 issued U.S. patents, and multiple pending patents, covering materials, methods of production, systems incorporating the technology and multiple medical uses.</p> <!--EndFragment--></div> </div>
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1870612 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1729344 USD
CY1997Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1741839 USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
234402 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
141268 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
555186 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1870612 USD
CY2013Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
26699046 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
234402063 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
214967503 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
234402063 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
214967503 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
214968 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3047200 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2473906 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1415856 USD
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1047310 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-90870287 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Concentration of Credit Risk</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p> <!--EndFragment--></div> </div>
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
559 USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
399395 USD
CY2013Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
994982 USD
CY2012Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
612300 USD
CY2013Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
912107 USD
CY2012Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
926225 USD
CY2013Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
912107 USD
CY2012Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
926225 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
453066 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
20160 USD
CY2013Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
199555 USD
CY2012Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
10080 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1286937 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1226042 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
395153 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
13175491 USD
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
3951540 shares
CY2012 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
9739912 shares
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
8784000 shares
us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
85450 USD
us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
48912 USD
CY2013Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.125
CY2013Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1098000 USD
CY2012 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2013Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2013Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
185893 USD
CY2012Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
178775 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
31585 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21415 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2535606 USD
CY2013Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
102979296 USD
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
98732460 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3269 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-15931 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M26D
CY2013Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
131000 USD
us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
0.10
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
CY2013Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
CY2012Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
21663 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
CY2013Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
CY2012Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
216617 USD
us-gaap Gross Profit
GrossProfit
209747 USD
us-gaap Gross Profit
GrossProfit
113108 USD
CY2013Q2 us-gaap Gross Profit
GrossProfit
91928 USD
CY2012Q2 us-gaap Gross Profit
GrossProfit
72962 USD
us-gaap Gross Profit
GrossProfit
1755335 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3043931 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2473906 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1414989 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1047310 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-91793430 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
939074 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
162428 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
60581 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3268232 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
32286 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7316 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
84065 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1823103 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-205822 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
104236 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
476550 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-9442 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
37511 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-320420 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
102340 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
427221 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
235762 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-214859 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-397177 USD
CY2013Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8147 USD
CY2012Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-37807 USD
CY2013Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
33000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-102979296 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
49000 USD
CY2013Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
113000 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
195000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
65468 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-7516409 USD
us-gaap Interest Paid
InterestPaid
USD
us-gaap Interest Paid
InterestPaid
USD
us-gaap Interest Paid
InterestPaid
590189 USD
CY2013Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
331000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
439000 USD
CY2013Q2 us-gaap Inventory Net
InventoryNet
476550 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
682372 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
95468 USD
CY2013Q2 us-gaap Liabilities
Liabilities
2104004 USD
CY2012Q4 us-gaap Liabilities
Liabilities
2076736 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2981011 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3339408 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2104004 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2076736 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2013067 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2800000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74467930 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35318 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26022 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4554319 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1833212 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2218792 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68027068 USD
us-gaap Net Income Loss
NetIncomeLoss
-3043931 USD
us-gaap Net Income Loss
NetIncomeLoss
-2473906 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-1414989 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-1047310 USD
us-gaap Net Income Loss
NetIncomeLoss
-90854356 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4246836 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3715027 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2031477 USD
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1624514 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
254220 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3269 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-214859 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-397177 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8147 USD
CY2012Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37807 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7639624 USD
us-gaap Operating Expenses
OperatingExpenses
3038819 USD
us-gaap Operating Expenses
OperatingExpenses
2189837 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
1498770 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
1082465 USD
us-gaap Operating Expenses
OperatingExpenses
85909141 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2829072 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2076729 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1406842 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1009503 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-84153806 USD
us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
USD
us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
USD
us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
74938 USD
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
251432 USD
CY2013Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-867 USD
CY2012Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15931 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3269 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
USD
us-gaap Other Noncash Expense
OtherNoncashExpense
USD
us-gaap Other Noncash Expense
OtherNoncashExpense
361496 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
USD
CY2013Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
USD
CY2012Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
361495 USD
us-gaap Other Operating Income
OtherOperatingIncome
USD
us-gaap Other Operating Income
OtherOperatingIncome
USD
CY2013Q2 us-gaap Other Operating Income
OtherOperatingIncome
USD
CY2012Q2 us-gaap Other Operating Income
OtherOperatingIncome
USD
us-gaap Other Operating Income
OtherOperatingIncome
6055483 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
USD
us-gaap Paid In Kind Interest
PaidInKindInterest
USD
us-gaap Paid In Kind Interest
PaidInKindInterest
3147 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
12769 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
24957 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
511283 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
393607 USD
us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
USD
us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
USD
us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
1632168 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22549 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1065 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2443359 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1202905 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1241121 USD
CY2013Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
616488 USD
CY2012Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
577204 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12124940 USD
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
1675 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
1594 USD
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
155673 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
476093 USD
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Reclassifications</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> Certain items for the periods ended June 30, 2012 have been reclassified to conform to the presentation at June 30, 2013. There was no change in net income as a result of these reclassifications.</p> <!--EndFragment--></div> </div>
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
899967 USD
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
2100000 USD
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
50971278 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
400490 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
9579040 USD
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
1098000 USD
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
700000 USD
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
12986881 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
15746 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
393607 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
32491 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15100 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
514495 USD
us-gaap Professional Fees
ProfessionalFees
412539 USD
us-gaap Professional Fees
ProfessionalFees
234827 USD
CY2013Q2 us-gaap Professional Fees
ProfessionalFees
189793 USD
CY2012Q2 us-gaap Professional Fees
ProfessionalFees
73535 USD
us-gaap Professional Fees
ProfessionalFees
8997674 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
142679 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145600 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
255882 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1412300 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1392364 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
708159 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
715750 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55341759 USD
us-gaap Revenue From Grants
RevenueFromGrants
358746 USD
us-gaap Revenue From Grants
RevenueFromGrants
83333 USD
CY2013Q2 us-gaap Revenue From Grants
RevenueFromGrants
163514 USD
CY2012Q2 us-gaap Revenue From Grants
RevenueFromGrants
50000 USD
us-gaap Revenue From Grants
RevenueFromGrants
2550553 USD
us-gaap Sales Revenue Net
SalesRevenueNet
3042272 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
304067 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
49935 USD
CY2013Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
127969 USD
CY2012Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
33042 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
491719 USD
us-gaap Sales Revenue Net
SalesRevenueNet
662813 USD
us-gaap Sales Revenue Net
SalesRevenueNet
133268 USD
CY2013Q2 us-gaap Sales Revenue Net
SalesRevenueNet
291483 USD
CY2012Q2 us-gaap Sales Revenue Net
SalesRevenueNet
83042 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1213980 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
562646 USD
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
600818 USD
CY2012Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
293180 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27625191 USD
us-gaap Service Management Costs
ServiceManagementCosts
USD
us-gaap Service Management Costs
ServiceManagementCosts
USD
us-gaap Service Management Costs
ServiceManagementCosts
1334285 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.28 pure
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
36667616 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.20
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.23
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.04
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.12
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.11
CY2013Q2 us-gaap Shares Held In Employee Stock Option Plan Allocated
SharesHeldInEmployeeStockOptionPlanAllocated
22750000 shares
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
-13185005 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.019 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.008 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
9402 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
13985000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
47911477 shares
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-11625145 USD
us-gaap Stock Issued1
StockIssued1
20632 USD
us-gaap Stock Issued1
StockIssued1
213584 USD
us-gaap Stock Issued1
StockIssued1
604118 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
496737 shares
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
20386 USD
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
65468 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
899967 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15100 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
266490 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
4532 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2834678 USD
us-gaap Use Of Estimates
UseOfEstimates
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Use of Estimates</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends and valuation methods used in determining any debt discount associated with convertible securities.</p> <!--EndFragment--></div> </div>
CY2013Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
103018 USD
CY2012Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
38788 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
227299644 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
187795284 shares
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
231583119 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
194439923 shares

Files In Submission

Name View Source Status
0001144204-13-045408-index-headers.html Edgar Link pending
0001144204-13-045408-index.html Edgar Link pending
0001144204-13-045408.txt Edgar Link pending
0001144204-13-045408-xbrl.zip Edgar Link pending
ctso-20130630.xml Edgar Link completed
ctso-20130630.xsd Edgar Link pending
ctso-20130630_cal.xml Edgar Link unprocessable
ctso-20130630_def.xml Edgar Link unprocessable
ctso-20130630_lab.xml Edgar Link unprocessable
ctso-20130630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
v352114_10q.htm Edgar Link pending
v352114_ex31-1.htm Edgar Link pending
v352114_ex31-2.htm Edgar Link pending
v352114_ex32-1.htm Edgar Link pending
v352114_ex32-2.htm Edgar Link pending